BTG gets US clearance for proposed £3.3bn Boston Scientific deal

FTSE 250 medical technology company BTG said on Wednesday that its proposed £3.3bn acquisition by Boston Scientific has received merger clearance from the US Federal Trade Commission.

The deal, which was announced last November, has already been approved by Austrian and Spanish authorities.

Under the terms of the acquisition agreed last year, BTG shareholders will receive 840p in cash for each of their shares. This represents a 37% premium to the BTG closing price the day before the deal was announced.

BTG's chief executive Louise Makin said at the time: "Boston Scientific shares our commitment to transforming patient care, and has a sustained track record of innovation, clinical expertise and global commercial capabilities."

At 1200 BST, BTG shares were up 0.3% at 840p.